These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703 [TBL] [Abstract][Full Text] [Related]
4. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Demarchi LM; Reis MM; Palomino SA; Farhat C; Takagaki TY; Beyruti R; Saldiva PH; Capelozzi VL Mod Pathol; 2000 May; 13(5):511-20. PubMed ID: 10824922 [TBL] [Abstract][Full Text] [Related]
5. Prognostic features of surgical stage I uterine carcinosarcoma. Ferguson SE; Tornos C; Hummer A; Barakat RR; Soslow RA Am J Surg Pathol; 2007 Nov; 31(11):1653-61. PubMed ID: 18059221 [TBL] [Abstract][Full Text] [Related]
6. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report. Semczuk A; Skomra D; Chyzyńska M; Szewczuk W; Olcha P; Korobowicz E Pathol Res Pract; 2008; 204(3):203-7. PubMed ID: 18207653 [TBL] [Abstract][Full Text] [Related]
8. Proliferation indices and p53-immunocytochemistry in uterine mixed mullerian tumors. Nicòtina PA; Ferlazzo G; Vincelli AM Histol Histopathol; 1997 Oct; 12(4):967-72. PubMed ID: 9302556 [TBL] [Abstract][Full Text] [Related]
9. Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Bodner-Adler B; Bodner K; Obermair A; Czerwenka K; Petru E; Leodolter S; Mayerhofer K Anticancer Res; 2001; 21(4B):3069-74. PubMed ID: 11712812 [TBL] [Abstract][Full Text] [Related]
10. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714 [TBL] [Abstract][Full Text] [Related]
11. Carcinoma (malignant mixed müllerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases. Costa MJ; Khan R; Judd R Arch Pathol Lab Med; 1991 Jun; 115(6):583-90. PubMed ID: 1710102 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
13. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours? Plastiras D; Moutzouris G; Barbatis C; Presvelos V; Petrakos M; Theodorou C Eur J Surg Oncol; 1999 Feb; 25(1):61-5. PubMed ID: 10188857 [TBL] [Abstract][Full Text] [Related]
14. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189 [TBL] [Abstract][Full Text] [Related]
15. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225 [TBL] [Abstract][Full Text] [Related]
16. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905 [TBL] [Abstract][Full Text] [Related]
17. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma]. Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998 [TBL] [Abstract][Full Text] [Related]
18. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626 [TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of the immunohistochemical expression of: Ki67, p53, PCNA and Bcl2 in the superficial tumors of the bladder]. Rammeh-Rommani S; Zermani R; Sfaxi M; Chabchoub A; Zouari B; Ayed M; Ben Jilani-Baltagi S Tunis Med; 2007 Jun; 85(6):509-12. PubMed ID: 17644907 [TBL] [Abstract][Full Text] [Related]
20. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]